GURU.Markets stock price, segment price, and overall market index valuation
The company's share price MoonLake Immunotherapeutics
MoonLake, a biotech focused on treating inflammatory diseases, shares reflect the potential of its lead drug. The price chart is a classic biotech story, with the value determined by expectations of clinical trial results.
Share prices of companies in the market segment - Pharma metabolism
MoonLake Immunotherapeutics is a biotech company focused on treating inflammatory diseases. We classify it as a pharmaceutical company (metabolism and immunology), and the chart below reflects the general trends and sentiment in this biotech field.
Broad Market Index - GURU.Markets
MoonLake Immunotherapeutics is a biopharmaceutical company developing nanobody-based treatments for inflammatory skin and joint diseases. As a component of the GURU.Markets index, it represents the biotech sector. The chart below represents the entire market. See how MoonLake shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
MLTX - Daily change in the company's share price MoonLake Immunotherapeutics
For MoonLake Immunotherapeutics, a biopharmaceutical company, change_co is a measure of the sector's inherently high volatility. Each daily change reflects sensitivity to news about clinical trials of its drugs. This metric isn't just noise, but a critical component of the models on System.GURU.Markets that assess risk in innovative medicine.
Daily change in the price of a set of shares in a market segment - Pharma metabolism
MoonLake Immunotherapeutics is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with MLTX's performance, which depends on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
MoonLake Immunotherapeutics is a biopharmaceutical company specializing in drugs for the treatment of inflammatory diseases. Immunology is a cutting-edge but highly volatile segment of biotechnology. The chart below shows average daily fluctuations in this area, allowing you to assess MoonLake's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization MoonLake Immunotherapeutics
MoonLake is a biotech company focused on immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Annual dynamics of market capitalization of the market segment - Pharma metabolism
MoonLake Immunotherapeutics is a clinical-stage biotech company developing innovative drugs for the treatment of inflammatory diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs in this complex area of medicine.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
MoonLake is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the key events are data releases, not macroeconomic statistics.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization MoonLake Immunotherapeutics
MoonLake, a biopharmaceutical company developing drugs to treat inflammatory skin and joint diseases, has sharp monthly fluctuations reflecting news about clinical trials of its main asset, which is typical for development-stage biotechs.
Monthly dynamics of market capitalization of the market segment - Pharma metabolism
MoonLake Immunotherapeutics is a clinical-stage biotech company developing drugs for the treatment of inflammatory skin and joint diseases. Its research is based on a "nanobody" molecule. The chart below shows the overall dynamics of the biotech sector, where investors are betting on innovative scientific approaches.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
MoonLake Immunotherapeutics is a biotech company developing a nanobody-based drug for the treatment of inflammatory skin and joint diseases. The chart below shows general market trends, but MoonLake shares move with clinical trial news, not the broader market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biotech developing treatments for inflammatory diseases, exhibits volatility typical for the sector. Its weekly stock price performance is almost entirely dependent on news about clinical trials and regulatory decisions, rather than on overall market trends.
Weekly dynamics of market capitalization of the market segment - Pharma metabolism
Biotech companies working in immunology, like MoonLake, are riding the wave of general news about scientific breakthroughs in this field. The chart below illustrates this general sentiment. It allows one to assess how promising the market perceives MoonLake's technology compared to other companies in the field.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
MoonLake Immunotherapeutics is a clinical-stage biotech company developing drugs to treat inflammatory diseases. Its shares move not with the market, but rather on expectations for trial results. The chart will show how unpredictable its performance is and how independent it is of macroeconomic factors.
Market capitalization of the company, segment and market as a whole
MLTX - Market capitalization of the company MoonLake Immunotherapeutics
MoonLake Immunotherapeutics' market capitalization reflects investors' assessment of the potential of its nanobody for treating inflammatory skin diseases. The chart shows the market's high confidence that its drug could become best-in-class for treating, for example, hidradenitis suppurativa. Its high valuation reflects the huge potential market and patient expectations.
MLTX - Share of the company's market capitalization MoonLake Immunotherapeutics within the market segment - Pharma metabolism
MoonLake Immunotherapeutics is a biotech company whose market share reflects the potential of its lead drug for treating inflammatory skin and joint diseases. Its market capitalization is based on expectations for clinical trial results.
Market capitalization of the market segment - Pharma metabolism
This chart shows the total value of the entire biotech sector focused on treating immune diseases. For MoonLake Immunotherapeutics, which is developing an innovative drug for skin and joint diseases, this line demonstrates the scale of the market. The rising chart reflects the enormous need for new, more effective treatments for these chronic conditions.
Market capitalization of all companies included in a broad market index - GURU.Markets
MoonLake Immunotherapeutics develops drugs for the treatment of inflammatory skin and joint diseases. Its market capitalization is a bet on a new approach to treating chronic diseases. In the overall market, this represents a significant portion of the hope for improving the quality of life for millions of patients.
Book value capitalization of the company, segment and market as a whole
MLTX - Book value capitalization of the company MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a biotech company developing drugs to treat inflammatory diseases. Its book value is the sum of its clinical trial reserves and the value of its intellectual property. This represents its scientific and financial capital. How has this changed? The chart below shows.
MLTX - Share of the company's book capitalization MoonLake Immunotherapeutics within the market segment - Pharma metabolism
MoonLake Immunotherapeutics develops nanobody-based drugs, and its innovations require a specific resource base. This includes investments in laboratories and technological platforms for working with this new class of biological molecules. The chart shows the company's share of the R&D infrastructure for this cutting-edge field in immunology.
Market segment balance sheet capitalization - Pharma metabolism
MoonLake Immunotherapeutics develops drugs to treat inflammatory diseases. Pharmaceuticals, as the graph shows, are both knowledge- and capital-intensive. MoonLake is an R&D company, its capital not in factories, but in the intellectual property of innovative molecules.
Book value of all companies included in the broad market index - GURU.Markets
MoonLake Immunotherapeutics develops innovative treatments for inflammatory diseases. Its book value is derived from its cutting-edge nanobody technology, laboratories, and capital for clinical trials. The chart shows the material foundation upon which hopes for new therapies for millions of patients are built.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - MoonLake Immunotherapeutics
MoonLake Immunotherapeutics' balance sheet is capital. But the market sees the potential of its unique nanobody for treating inflammatory diseases. The chart shows a huge "hope factor": a premium for the belief that its development will be a medical breakthrough.
Market to book capitalization ratio in a market segment - Pharma metabolism
MoonLake Immunotherapeutics is a biotech company developing drugs for the treatment of inflammatory skin and joint diseases. Its valuation is based on the potential of its molecule, sonodelimab. The chart reflects investors' high expectations for clinical trial results.
Market to book capitalization ratio for the market as a whole
MoonLake Immunotherapeutics is a clinical-stage biotech company developing nanobodies for the treatment of inflammatory skin and joint diseases. Its assets include a scientific platform and patents. This chart shows the overall market valuation, but how do investors evaluate the potential of this new technology for treating chronic immune disorders?
Debts of the company, segment and market as a whole
MLTX - Company debts MoonLake Immunotherapeutics
For MoonLake, a clinical-stage biotech company, the financial strategy is focused on supporting research. Debt capital, particularly venture capital, can be a way to extend the financing period until key clinical trial milestones are achieved, thereby increasing the company's value.
Market segment debts - Pharma metabolism
MoonLake is a clinical-stage biopharmaceutical company developing drugs to treat inflammatory diseases. Without sales revenue, such companies are entirely dependent on external funding to conduct expensive research. This chart shows the company's chosen financing strategy: classic equity financing or the more uncommon debt financing.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotech developing drugs to treat inflammatory diseases. This chart shows its financial position. Like many development-stage biotechs, it is likely equity-financed, allowing it to conduct expensive clinical trials without the burden of interest payments.
Market segment debt to market segment book capitalization - Pharma metabolism
Developing drugs to treat autoimmune diseases, MoonLake's focus, is a promising area of biotechnology that requires significant investment. This chart shows how the sector as a whole funds R&D. It allows one to assess the financial model of a young company working on innovative solutions against the backdrop of the pharmaceutical industry, dominated by giants.
Debt to book value of all companies in the market
This chart shows the overall "credit appetite" of the entire economy. MoonLake, an early-stage biotech company, is entirely dependent on investors. Comparison with the overall market, comprised of profitable businesses, clearly demonstrates how different a financial model based on future scientific breakthroughs, rather than current sales, is from traditional economics.
P/E of the company, segment and market as a whole
P/E - MoonLake Immunotherapeutics
For MoonLake Immunotherapeutics, a biotech developing treatments for inflammatory diseases, this chart illustrates investor expectations. Like many clinical biotechs, its value is based not on profits, but on the potential of its molecule to become a breakthrough drug for a range of diseases.
P/E of the market segment - Pharma metabolism
Immunology, where MoonLake develops new drugs, is a promising field. This chart shows the average valuation for biopharmaceutical companies. It helps us understand that MoonLake is valued as a scientific platform whose developments could lead to breakthroughs in the treatment of inflammatory diseases, and its valuation is based on this future potential.
P/E of the market as a whole
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company specializing in the development of innovative treatments for inflammatory skin and joint diseases. This chart reflects the overall investor risk appetite in the biotech sector. It helps us understand whether MLTX's valuation is based on the potential of its lead drug or whether it moves in line with overall industry sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotech company developing drugs for the treatment of inflammatory skin and joint diseases. This chart reflects the high investor expectations for its lead candidate, sonrucimab. Its trend reflects the success of clinical trials and the future commercial potential of this innovative drug.
%20P%2FE%20MoonLake%20Immunotherapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-MoonLake-Immunotherapeutics&v=1772513860371 "Chart of the company's future (projected) P/E MoonLake Immunotherapeutics")
Future (projected) P/E of the market segment - Pharma metabolism
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company developing treatments for inflammatory skin and joint diseases. This chart shows its future profitability expectations, allowing us to assess how highly the market values the potential of its innovative immunology developments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-metabolism&v=1772513860386 "Future (projected) P/E graph of the market segment - Pharma metabolism")
Future (projected) P/E of the market as a whole
MoonLake Immunotherapeutics is a clinical-stage biotech company developing a treatment for inflammatory skin and joint diseases. Its value is based solely on the potential of a single asset. MoonLake's valuation is not tied to overall market forecasts, but depends on trial results.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513860401 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company developing drugs for the treatment of inflammatory skin and joint diseases. Its financial metrics reflect its investment in research. This chart shows how much the company is investing in clinical trials of its main asset, sonolikimab, in hopes of achieving future commercial success.
Profit of companies in the market segment - Pharma metabolism
MoonLake Immunotherapeutics is a clinical-stage biotech company developing nanobodies for the treatment of inflammatory skin and joint diseases. Their approach promises greater efficacy. This chart illustrates the overall dynamics in the immunology sector, where scientific breakthroughs could lead to the creation of blockbuster drugs for the treatment of chronic diseases.
Overall market profit
MoonLake Immunotherapeutics is a clinical-stage biotech company developing drugs to treat inflammatory diseases. Its valuation represents the hope for future treatments. Access to funding for research depends on investor sentiment, which often correlates with the overall health of the economy, as reflected in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company developing nanobody-based therapies for the treatment of inflammatory skin and joint diseases. This cutting-edge technology aims to create more effective medications. This chart shows analysts' assessments of the company's likelihood of success and future commercial potential.
%20profit%20of%20the%20company%20MoonLake%20Immunotherapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-MoonLake-Immunotherapeutics&v=1772513860430 "Graph of future (projected) profit of the company MoonLake Immunotherapeutics")
Future (predicted) profit of companies in the market segment - Pharma metabolism
MoonLake Immunotherapeutics is a clinical-stage biotechnology company developing nanobody-based therapies for the treatment of inflammatory skin and joint diseases. This technology enables the creation of more potent and easier-to-use medications. This chart shows profitability projections for the biotech sector, providing context for assessing the potential of MoonLake's innovative platform.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-metabolism&v=1772513860440 "Graph of future (predicted) profits of companies in a market segment - Pharma metabolism")
Future (predicted) profit of the market as a whole
MoonLake Immunotherapeutics is a clinical-stage biotech company focused on treating inflammatory diseases. Its value is determined solely by scientific data, trial results, and the potential market size of its drugs. Its prospects are not linked to the macroeconomic forecasts presented in this chart.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513860448 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotech company. This chart is a proxy for future expectations. The market value relative to revenue reflects investor confidence in the potential of its drugs to treat inflammatory diseases.
P/S market segment - Pharma metabolism
MoonLake Immunotherapeutics is a biotech company developing nanobody-based therapies for the treatment of inflammatory skin and joint diseases. This chart shows the average revenue estimate in the biotech sector. It allows you to assess how highly investors value the potential revenue from MoonLake's innovative technology and its drug candidates.
P/S of the market as a whole
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company developing nanobody-based therapies for the treatment of inflammatory skin and joint diseases. Their technology promises more effective therapy. This chart provides a general revenue metric, which underscores the high expectations investors have for MLTX's innovative scientific platform.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a biotech company developing nanobody-based therapies for the treatment of inflammatory skin and joint diseases. This chart reflects investors' high expectations for its future sales. The valuation is based on the potential of its lead candidate, sonrucimab, to offer a more effective and convenient treatment.
%20P%2FS%20MoonLake%20Immunotherapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-MoonLake-Immunotherapeutics&v=1772513860612 "The graph of the company's future (projected) P/S MoonLake Immunotherapeutics")
Future (projected) P/S of the market segment - Pharma metabolism
MoonLake Immunotherapeutics is a biopharmaceutical company developing treatments for inflammatory diseases based on its Nanobody® technology. Its core asset has significant potential. This chart compares the market's high expectations for its lead drug with those of competitors in the immunology and biotech sectors.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-metabolism&v=1772513860724 "Future (projected) P/S market segment graph - Pharma metabolism")
Future (projected) P/S of the market as a whole
MoonLake Immunotherapeutics is a clinical-stage biotech developing drugs to treat inflammatory diseases. This chart, reflecting overall market sentiment, is critical to its funding. Investor optimism and risk appetite allow companies like MoonLake to raise the significant funds needed to conduct costly clinical trials.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513860803 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company developing drugs for the treatment of inflammatory skin and joint diseases. This chart depicts its financial flows, which at this stage likely consist of investor funding and partner fees rather than commercial sales. It illustrates its investment in advanced immunology.
Sales of companies in the market segment - Pharma metabolism
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company specializing in the development of nanobody-based treatments for inflammatory diseases such as psoriasis and arthritis. Its activities are segmented by development programs. This chart displays the financial flows associated with one of its lead candidates, demonstrating its progress.
Overall market sales
MoonLake Immunotherapeutics is a clinical-stage biotechnology company developing drugs for the treatment of inflammatory skin and joint diseases. Its value is determined by scientific potential and the success of clinical trials. The company is working to create new therapeutic options for millions of patients, potentially significantly improving their quality of life.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company developing an innovative drug (sonolikimab) for the treatment of inflammatory skin and joint diseases. The sales forecast is the market's assessment of the drug's potential to become best-in-class if it successfully completes clinical trials and receives approval.
%20sales%20of%20the%20company%20MoonLake%20Immunotherapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-MoonLake-Immunotherapeutics&v=1772513860910 "Schedule of future (projected) sales of the company MoonLake Immunotherapeutics")
Future (projected) sales of companies in the market segment - Pharma metabolism
MoonLake Immunotherapeutics is a clinical-stage biotechnology company developing drugs for the treatment of inflammatory skin and joint diseases. This chart shows expectations for the entire immunology sector. It reflects analysts' views on the potential of new treatments and the market size for psoriasis and arthritis drugs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-metabolism&v=1772513860927 "Schedule of future (projected) sales of companies in the market segment - Pharma metabolism")
Future (projected) sales of the market as a whole
MoonLake Immunotherapeutics, a biotech company developing treatments for inflammatory diseases, is in clinical trials. Its valuation depends on investor confidence in its scientific potential. This chart of total sales forecasts reflects market sentiment, which impacts the availability of capital for such companies.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513860935 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company specializing in the development of drugs for the treatment of inflammatory skin and joint diseases. This chart reflects its current financial position, where significant investments in research and development are key to the development of future commercially successful products.
Market segment marginality - Pharma metabolism
MoonLake Immunotherapeutics is a clinical-stage biotechnology company developing a nanobody-based treatment for inflammatory skin and joint diseases. Their technology promises increased efficacy and convenience for patients. This graph provides an idea of the potential operational effectiveness of their innovative approach if it proves viable.
Market marginality as a whole
MoonLake Immunotherapeutics is a biotech company developing drugs for the treatment of inflammatory skin and joint diseases. Its value is based on the potential of its lead drug candidate. This chart shows the profitability of mature businesses, while MLTX's success depends on clinical trial results and the ability to bring a new, effective treatment to market.
Employees in the company, segment and market as a whole
Number of employees in the company MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company developing drugs for the treatment of inflammatory diseases. This chart shows the growth of its scientific team. This increase in intellectual capital is a key indicator of progress in clinical trials of its promising nanobody.
Share of the company's employees MoonLake Immunotherapeutics within the market segment - Pharma metabolism
MoonLake Immunotherapeutics is a clinical-stage biotechnology company developing drugs for the treatment of inflammatory diseases. Its strategy is to rapidly advance promising molecules through clinical trials. This schedule reflects its focused investment in its team of specialists to accelerate development.
Number of employees in the market segment - Pharma metabolism
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company developing drugs to treat inflammatory diseases. This chart reflects employment in the pharmaceutical sector. The growing number of immunology researchers reflects profound advances in understanding inflammatory processes and active investment in developing new treatments.
Number of employees in the market as a whole
MoonLake Immunotherapeutics is a clinical-stage biotech company. Its primary focus is raising capital for research. A strong, high-employment economy creates a favorable stock market environment, making it easier for small biotech companies like MoonLake to raise funds for their developments.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics is a clinical-stage biotech company developing drugs for the treatment of inflammatory diseases. Its staff is small, but consists of leading scientists. The astronomically high market capitalization per employee, reflected in this chart, reflects the market's bet on the intellectual property and potential of its candidate molecule.
%20of%20the%20company%20MoonLake%20Immunotherapeutics%20(MLTX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-MoonLake-Immunotherapeutics-MLTX&v=1772513861062 "Chart of market capitalization per employee (in thousands of dollars) of the company MoonLake Immunotherapeutics (MLTX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma metabolism
MoonLake (MLTX) is a clinical-stage biotech company working in immunology. Its value comes from pure R&D and the hope of a future breakthrough. This chart shows the (speculative) market value the market attributes to each elite scientist, not its current operations.
%20by%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-metabolism&v=1772513861093 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma metabolism")
Market capitalization per employee (in thousands of dollars) for the overall market
MoonLake Immunotherapeutics is a clinical-stage biotech developing drugs for the treatment of inflammatory diseases. Its value reflects the hope for success of its key asset, sonadelgimab. The chart reflects the market's high speculative valuation of the potential generated by a small scientific team.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513861100 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics (MLTX) is a clinical-stage biotech developing nanobody-based drugs for the treatment of inflammatory skin and joint diseases. Like other biotechs, its profit per employee is likely negative. This chart shows how much capital the company burns per scientist in R&D, striving to create a new class of drugs.
%20Chart%20MoonLake%20Immunotherapeutics%20(MLTX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-MoonLake-Immunotherapeutics-MLTX&v=1772513861134 "Company Profit Per Employee (in thousands of dollars) Chart MoonLake Immunotherapeutics (MLTX)")
Profit per employee (in thousands of dollars) in the market segment - Pharma metabolism
MoonLake (MLTX) is an R&D company developing "tri-specific" nanobodies for the treatment of inflammatory diseases (psoriasis). This chart shows the benchmark for "Pharma Metabolism" (Biotech). In this R&D sector, the benchmark is *negative*. Companies are burning billions on R&D. Profit per scientist is the goal of the future.
%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-metabolism&v=1772513861203 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma metabolism")
Profit per employee (in thousands of dollars) for the market as a whole
MoonLake (MLTX) is a Swiss biotech company using nanobody technology to develop drugs for chronic inflammatory and autoimmune diseases. This graph, showing average profit per employee, is important for biotech. It allows us to assess how much a sector where a handful of scientists can create a breakthrough drug outperforms the "average" labor efficiency.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513861216 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics is a clinical-stage biotech company developing drugs for the treatment of inflammatory diseases. Currently, revenue per employee may be nonexistent. This graph is an indicator of future potential: whether their innovative development can become a commercially successful product.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-MoonLake-Immunotherapeutics-MLTX&v=1772513861221 "Sales chart per company employee MoonLake Immunotherapeutics (MLTX)")
Sales per employee in the market segment - Pharma metabolism
MoonLake Immunotherapeutics is a biotech company developing nanobody-based drugs for the treatment of chronic inflammatory skin and joint diseases. This chart shows revenue per employee. For a company in the R&D stage, the comparison to the segment reflects the efficiency of resource management on the path to commercialization.
Sales per employee for the market as a whole
MoonLake Immunotherapeutics is a clinical-stage biotech developing drugs for the treatment of inflammatory skin and joint diseases. Like other biotechs at this stage (AKRO, MTSR), they likely do not yet have commercial revenue. This graph will reflect $0 or partnership revenue, as the company's focus is on R&D.
Short shares by company, segment and market as a whole
Shares shorted by company MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics is a biotech company developing a drug (sonoliocyme) for the treatment of inflammatory skin and joint diseases (such as psoriasis). This is a highly competitive market, dominated by blockbusters from giants. This chart shows the number of investors who doubt MoonLake's drug will be competitive.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-MoonLake-Immunotherapeutics-MLTX&v=1772513861258 "Short Shares Chart for the Company MoonLake Immunotherapeutics (MLTX)")
Shares shorted by market segment - Pharma metabolism
MoonLake Immunotherapeutics (MLTX) is a biotech company developing nanobody-based drugs for the treatment of chronic inflammatory skin and joint diseases. This chart shows the odds against the immunology sector, reflecting the high level of investor skepticism regarding the success of clinical trials in a competitive environment already teeming with blockbusters.
Shares shorted by the overall market
MoonLake (MLTX) is a clinical-stage biotech (immunology). This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk, especially unprofitable biotechs. This pessimism, visible on the chart, deprives MLTX of access to the capital needed for expensive trials.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics is a clinical-stage biotech. Its shares are highly sensitive to trial news. This chart for MLTX can surge above 70 on positive R&D data. Oversold levels (<30) often reflect research setbacks or general risk aversion.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-MoonLake-Immunotherapeutics-MLTX&v=1772513861384 "RSI 14 indicator chart for the company's stock MoonLake Immunotherapeutics (MLTX)")
RSI 14 Market Segment - Pharma metabolism
MoonLake (MLTX) is a biotech company developing nanobodies (Sonelokimab) for the treatment of inflammatory diseases (e.g., psoriasis). The RSI_14_Seg for their segment (biotech/immunology) shows the overall sentiment. It helps us understand whether MLTX's volatility is a reaction to their trials or general hype.
RSI 14 for the overall market
MoonLake (MLTX) is a biotech company developing treatments for immune diseases. Like any biotech in the R&D stage, it is completely dependent on this schedule. Market euphoria allows it to raise capital. Market panic means investors flee unprofitable companies, and MLTX could face a funding crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast MLTX (MoonLake Immunotherapeutics)
MoonLake Immunotherapeutics is a biotech company developing drugs (sonortuvec) for the treatment of chronic inflammatory skin and joint diseases. This chart shows the average analyst forecast, representing their collective bet on the success of clinical trials and the drug's ability to compete in a crowded but profitable market.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-MLTX-MoonLake-Immunotherapeutics&v=1772513861421 "A chart showing analyst consensus forecasts for the expected stock price. MLTX (MoonLake Immunotherapeutics)")
The difference between the consensus estimate and the actual stock price MLTX (MoonLake Immunotherapeutics)
MoonLake is a clinical-stage biotech company developing nanobodies for the treatment of chronic inflammatory skin and joint diseases. This chart shows the difference between the consensus estimate and the price. It reflects analysts' belief in the breakthrough potential of this R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-MLTX-MoonLake-Immunotherapeutics&v=1772513861422 "A chart showing the difference between the consensus forecast and the actual stock price. MLTX (MoonLake Immunotherapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma metabolism
MoonLake is a biotech company focused on developing drugs to treat chronic inflammatory diseases (such as psoriasis). This chart shows analysts' overall expectations for the "metabolism" sector. It reflects whether experts believe breakthroughs in immune disease treatments are possible or whether the sector is overexposed.
Analysts' consensus forecast for the overall market share price
MoonLake Immunotherapeutics is a biotech company specializing in the treatment of inflammatory skin and joint diseases (such as psoriasis). This chart shows overall market sentiment. For MoonLake, as a development-stage biotech, it's important to understand how overall risk appetite (analyst sentiment) influences investor willingness to fund its clinical trials. (346)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index MoonLake Immunotherapeutics
MoonLake (MLTX) is a clinical-stage biotech focused on developing drugs for the treatment of inflammatory skin and joint diseases (psoriasis, arthritis). This chart represents a high-risk R&D bet. Its valuation is not tied to current revenue but reflects investors' faith in their scientific platform (nanobodies) and the results of their clinical trials.
AKIMA Market Segment Index - Pharma metabolism
MoonLake is a biotech innovator focused on immunology; the company is developing a miniature nano-protein (Nanobody) that targets key inflammatory pathways (IL-17) for the treatment of psoriasis. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does this innovative (Nanobody) MLTX R&D platform differentiate it from the average pharma company?
The AKIM Index for the overall market
MoonLake is a biotech company focused on immunology. It develops drugs (antibodies) for the treatment of chronic inflammatory diseases (skin, joints). This is a high-risk scientific bet. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this speculative story fits in with overall economic trends.
